FDA Approves TALZENNA — U.S. Pharmaceuticals

On October 16, 2018, U.S. Pharmaceuticals received FDA approval for Talzenna (talazoparib tosylate), a targeted oral therapy for advanced breast cancer. The approval expands the manufacturer’s oncology portfolio and strengthens its position in the rapidly growing PARP inhibitor market.